Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.0101 | 0 | 0.5 |
Trypanosoma cruzi | glycogen synthase kinase 3, putative | 0.0101 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0101 | 0 | 0.5 |
Plasmodium vivax | glycogen synthase kinase 3, putative | 0.0101 | 0 | 0.5 |
Leishmania major | glycogen synthase kinase, putative;with=GeneDB:LinJ18_V3.0270 | 0.0101 | 0 | 0.5 |
Plasmodium falciparum | glycogen synthase kinase 3 | 0.0101 | 0 | 0.5 |
Echinococcus multilocularis | glutaminyl peptide cyclotransferase | 0.0336 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0101 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC GSK | 0.0101 | 0 | 0.5 |
Echinococcus granulosus | glutaminyl peptide cyclotransferase | 0.0336 | 1 | 1 |
Onchocerca volvulus | Glutaminyl cyclase homolog | 0.0336 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0101 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0336 | 1 | 1 |
Schistosoma mansoni | glutaminyl cyclase (M28 family) | 0.0336 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0101 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC GSK | 0.0101 | 0 | 0.5 |
Toxoplasma gondii | cell-cycle-associated protein kinase GSK, putative | 0.0101 | 0 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0101 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.13 uM | Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring pFCA-lux AB gene measured under aerobic condition after 8 days by luminescence analysis | ChEMBL. | 22148391 |
MIC (functional) | = 4.3 uM | Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 harboring pFCA-lux AB gene measured under anaerobic condition after 11 days by luminescence analysis | ChEMBL. | 22148391 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.